This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration


Boxer, Adam L., Lipton, Anne M., Womack, Kyle, Merrilees, Jennifer, Neuhaus, John, Pavlic, Danijela, Gandhi, Anisha, Red, Dana, Martin-Cook, Kristen, Svetlik, Doris, Miller, Bruce L.


Alzheimer Disease And Associated Disorders, Volume: 23, No.: 3, Pages.: 211-217

Year of Publication



There are currently no Food and Drug Administration-approved treatments for frontotemporal lobar degeneration (FTLD). The objectives of this study were to explore the tolerability of memantine treatment in FTLD and to monitor for possible effects on behavior, cognition, and function. Forty-three individuals who met clinical criteria for FTLD [21 with frontotemporal dementia (FTD), 13 with semantic dementia (SD), and 9 with progressive nonfluent aphasia (PA)] received 26 weeks of open-label treatment with memantine at a target dose of 20 mg daily. Concurrent treatment with acetylcholinesterase inhibitors was prohibited. Cognitive and functional outcome measures included the Mini Mental State Examination, Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-cog), clinical dementia rating-sum of boxes, Neuropsychiatric Inventory (NPI), Frontal Behavior Inventory, Executive Interview (EXIT25), Texas Functional Living Scale (TFLS), Geriatric Depression Scale, and Unified Parkinson’s Disease Rating Scale-motor scale. Most subjects were able to tolerate the target dose of memantine. A transient improvement was observed on the total NPI score primarily in the FTD group. Variable declines were observed on the ADAS-cog, EXIT25, Frontal Behavior Inventory, NPI, TFLS, and UPDRS scores. The FTD and SD groups declined on most of the cognitive and behavioral outcome measures, but remained stable on the UPDRS, whereas the progressive nonfluent aphasia group remained relatively stable on the ADAS-cog, NPI, and TFLS, but declined on the UPDRS. Memantine was well-tolerated in these subjects. Future placebo-controlled trials of memantine in FTLD are warranted and may have greater power to detect behavioral and cognitive effects if focused on the FTD and SD clinical syndromes.;

Bibtex Citation

@article{Boxer_2009, doi = {10.1097/wad.0b013e318197852f}, url = {}, year = 2009, month = {jul}, publisher = {Ovid Technologies (Wolters Kluwer Health)}, volume = {23}, number = {3}, pages = {211--217}, author = {Adam L. Boxer and Anne M. Lipton and Kyle Womack and Jennifer Merrilees and John Neuhaus and Danijela Pavlic and Anisha Gandhi and Dana Red and Kristen Martin-Cook and Doris Svetlik and Bruce L. Miller}, title = {An Open-label Study of Memantine Treatment in 3 Subtypes of Frontotemporal Lobar Degeneration}, journal = {Alzheimer Disease {&} Associated Disorders} }


aged, cognition, dopamine agents, drug effects, drug therapy, female, frontotemporal lobar degeneration, humans, male, memantine, middle aged, neuropsychological tests, therapeutic use

Countries of Study


Types of Dementia

Fronto Temporal (also known as Pick’s Disease)

Types of Study

Cohort Study

Type of Outcomes

Behaviour, Cognition, Prevention and/or management of co-morbidities

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime